References
Remington G, Saha A, Chong SA, et al. Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 2005; 19(10): 843–72
Kontaxakis VP, Ferentinos PP, Havaki-Kontaxaki BJ, et al. Randomized controlled augmentation trials in clozapine-resistant schizophrenic patients: a critical review. Eur Psychiatry 2005; 20: 409–15
Emsley R, Myburgh C, Oosthuizen P, et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159: 1596–8
Fenton W, Dickerson FB, Boronow JJ, et al. Placebo-controlled trial of omega-3 fatty acid in schizophrenia. Schizophrenia Research 2001; 49 Suppl 1-2: 227
Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7–18
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Remington, G., Saha, A., Chong, SA. et al. Augmenting Strategies in Clozapine-Resistant Schizophrenia. CNS Drugs 20, 171 (2006). https://doi.org/10.2165/00023210-200620020-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200620020-00008